Trending: Bristol Myers Squibb to Buy RayzeBio
26 Dezember 2023 - 4:28PM
Dow Jones News
0958 ET -- Bristol Myers Squibb is one of the most mentioned
companies in the U.S. across all news items in the last 12 hours,
according to Factiva data. The drugmaker has agreed to buy
radiopharmaceutical therapeutics company RayzeBio for $4.1 billion.
Dow Jones & Co. owns Factiva. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
December 26, 2023 10:13 ET (15:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
RayzeBio (NASDAQ:RYZB)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
RayzeBio (NASDAQ:RYZB)
Historical Stock Chart
Von Jul 2023 bis Jul 2024